Molecular Partners AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MOLN research report →
About the company
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema.
- CEO
- Patrick Amstutz
- IPO
- 2021
- Employees
- 158
- HQ
- Schlieren, CH
Price Chart
- Market Cap
- $149.29M
- P/E
- -2.04
- P/S
- 0.00
- P/B
- 1.74
- EV/EBITDA
- -0.78
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -66.19%
- ROIC
- -69.14%
- Revenue
- $0 · -100.00%
- Net Income
- $-61,651,000 · -14.08%
- EPS
- $-1.65 · -3.77%
- Op Income
- $-58,124,000
- FCF YoY
- 13.34%
- 52W High
- $5.36
- 52W Low
- $3.41
- 50D MA
- $4.02
- 200D MA
- $4.17
- Beta
- 0.67
- Avg Volume
- 6.13K
Get TickerSpark's AI analysis on MOLN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MOLN coverage
Recent articles, reports, and earnings notes.
No research on MOLN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MOLN report →Similar companies
Peers in the same neighborhood.